TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report issued to clients and investors on Monday. The firm set a “hold” rating on the stock.

TherapeuticsMD Price Performance

Shares of TXMD stock opened at $1.72 on Monday. The firm has a 50 day moving average of $1.77 and a two-hundred day moving average of $1.96. TherapeuticsMD has a 52 week low of $1.43 and a 52 week high of $3.47.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million during the quarter.

Institutional Investors Weigh In On TherapeuticsMD

Institutional investors have recently modified their holdings of the company. Prosperity Consulting Group LLC acquired a new position in TherapeuticsMD in the first quarter valued at approximately $56,000. ADAR1 Capital Management LLC purchased a new stake in shares of TherapeuticsMD during the 4th quarter worth approximately $612,000. Finally, Clearline Capital LP lifted its position in shares of TherapeuticsMD by 18.9% during the 2nd quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock worth $1,025,000 after buying an additional 101,282 shares during the last quarter. 30.74% of the stock is owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.